Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Ashish Kamat Interview - BOND-003 Study Results

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Jan 09, 2024 12:53pm

172 Views

Post# 35817644

RE:Dr. Ashish Kamat Interview - BOND-003 Study Results

The constant need for maintenance treatments leads one to deduct that they probably have a lot of pseudo CR's. If they would stop treating after induction CR rates would probably drop considerably going forward IMHO Basically this treatment it's like saying we should retreat every 3 months with Ruvidar, as we would probably maintain 67-80% CR rate so long as you keep treating every 3 months IMHO

Eoganacht wrote: [url=https://www.urotoday.com/video-lectures/non-muscle-invasive-bladdercancer/video/mediaitem/3799-bond-003-phase-3-results-revolutionizing-bladder-cancer-treatment-with-intravesical-cretostimogene-grenadenorepvec-monotherapy-for-high-risk-bcg-unresponsive-nmibc-mark-tyson.htmlhttps://www.urotoday.com/video-lectures/non-muscle-invasive-bladdercancer/video/mediaitem/3799-bond-003-phase-3-results-revolutionizing-bladder-cancer-treatment-with-intravesical-cretostimogene-grenadenorepvec-monotherapy-for-high-risk-bcg-unresponsive-nmibc-mark-tyson.html]BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson[/url]

In this trial patients are treated many times.

"... in terms of treatment, patients underwent six sequential weekly instillations of creto, followed by a second induction course for non-responders or maintenance for responders, and maintenance was at three, six, nine, 12, and 18 months."

In this interim analysis of 66 patients the results were very good but not much better than Ruvidar PDT . The CRR at 12 months has not yet been revealed but the CR at any time, 6 month CR and 9 month CR numbers were announced. The 9 month results (which go unmentioned in the interview) are available from the swimmers plot at:

https://www.urotoday.com/conference-highlights/suo-2023/suo-2023-bladder-cancer/148306-suo-2023-late-breaking-abstract-first-results-from-bond-003-a-phase-3-study-of-intravesical-cretostimogene-grenadenorepvec-monotherapy-for-patients-with-high-risk-bcg-unresponsive-nmibc.html

CR at any time = 76%
CR at 6 months = 64%
CR at 9 months = 50%

In comparison, the optimized results of Ruvidar PDT are:

CR at any time = 67%
CR at 6 months = 60%
CR at 9 months = 50%
CR at 12 months = 36%

It's very cleat that Ruvidar PDT complete response rates hold up much better than those of CG0070.

At 9 months Ruvidar PDT has caught up with CG0070 in terms of durable complete response. When the 12 month BOND-003 data is revealed, Ruvidar PDT should have a better durable response rate than CG0070, despite the punishing treatment regime required to produce it..